PedAM
Pediatric Disease Annotations & Medicines
| conjunctivitis | ||||
| Disease ID | 1132 |
|---|---|
| Disease | conjunctivitis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:3) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:7) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0009763 | carbamazepine | D002220 | 298-46-4 | conjunctivitis | MESH:D003231 | marker/mechanism | 9072691 | ||
| C0009763 | celecoxib | D000068579 | - | conjunctivitis | MESH:D003231 | marker/mechanism | 16476901 | ||
| C0009763 | fluorouracil | D005472 | 51-21-8 | conjunctivitis | MESH:D003231 | marker/mechanism | 12918558 | ||
| C0009763 | methotrexate | D008727 | 1959/5/2 | conjunctivitis | MESH:D003231 | marker/mechanism | 6603024 | ||
| C0009763 | mitomycin | D016685 | 1950/7/7 | conjunctivitis | MESH:D003231 | marker/mechanism | 9759389 | ||
| C0009763 | rofecoxib | C116926 | - | conjunctivitis | MESH:D003231 | marker/mechanism | 16476901 | ||
| C0009763 | valdecoxib | C406224 | - | conjunctivitis | MESH:D003231 | marker/mechanism | 16476901 | ||
FDA approved drug and dosage information(Total Drugs:5) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D003231 | vioxx | rofecoxib | 12.5MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D003231 | vioxx | rofecoxib | 12.5MG/5ML | SUSPENSION;ORAL | Discontinued | None | No | No |
| MESH:D003231 | vioxx | rofecoxib | 12.5MG | TABLET; ORAL | Discontinued | None | No | No |
| MESH:D003231 | celebrex | celecoxib | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D003231 | celebrex | celecoxib | 100MG | CAPSULE;ORAL | Prescription | None | No | No |
FDA labeling changes(Total Drugs:5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D003231 | 08/19/2004 | vioxx | rofecoxib | Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis | Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004. | Labeling | B | - | - | - | Merck | 02/18/2004 | FALSE' |
| MESH:D003231 | 08/19/2004 | vioxx | rofecoxib | Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis | Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004. | Labeling | B | - | - | - | Merck | 02/18/2004 | FALSE' |
| MESH:D003231 | 08/19/2004 | vioxx | rofecoxib | Pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis | Merck announced a voluntary worldwide withdrawal of Vioxx (rofecoxib) due to safety concerns on September 30, 2004. | Labeling | B | - | - | - | Merck | 02/18/2004 | FALSE' |
| MESH:D003231 | 12/15/2006 | celebrex | celecoxib | Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) | New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs | Labeling | B | - | - | - | Pfizer | 08/23/2006 | FALSE' |
| MESH:D003231 | 12/15/2006 | celebrex | celecoxib | Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) | New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs | Labeling | B | - | - | - | Pfizer | 08/23/2006 | FALSE' |